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INTRODUCTION AND OBJECTIVE
A novel micro-encapsulation technology based on layer-by-layer 
assembly has been extensively studied and used for controlled 
delivery of drug microcrystal having poor aqueous solubility and 
low bioavailability [Qiu et al. 2001]. A non-steroidal anti-
inflammatory drug (Ketoprofen, KF) was selected for 
encapsulation using biodegradable and biocompatible polyions and 
synergistically the suspension was embedded in gel matrix for 
topical application. Topical application of the drugs at the 
pathological sites offer potential advantages of delivering the drug 
directly to the site of action and thus producing high tissue 
concentrations of the drug [Jain et. al. 2005]. 
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In the present investigation, we aimed to develop polyelectrolyte 
assembled multilayered KF mixed with gel for transdermal delivery, 
which effectively would manage the pain and inflammation in 
osteoarthritis and rheumatoid arthritis. Thus obtained data showed 
better effectiveness of the novel formulation. Further investigations 
are still underway to gather stability studies of developed 
formulation and for in-vivo performance by taking suitable model.
IN-VITRO KF RELEASE  PROFILE
• Topical application of polyelectrolyte multilayered assembly bearing 
ketoprofen at the pathological sites offers potentials advantages of 
delivering the drug directly to the site of action and thus producing 
high tissue concentrations of the drug. 
• Shape, surface morphology and narrow size distribution 
ranging from 2-4 µm of the KF micro-crystal and encapsulated 
KF presented by the particle size analyzer and Phase contract 
microscopy. 
• The effective adsorption of the PEs was evidenced by the zeta 
potential measurement.
•  In this novel approach we studied here, that the shell thickness of the 
capsule come ~100 nm, which is much smaller than the core drug 
crystal dimensions and gives a polymer shell to drug core thickness 
ratio of about 1:50. 
• A different release kinetic was observed for the both the 
formulations. Fick’s law of diffusion seems not to be applicable in each 
case. An initial rapid drug release was noted for F-1, whereas a lag 
time (~15 min) was observed with F-2 formulations which, could result 
from the time taken by the drug to diffuse across the gel. 
Mean particle size & size distribution of A. bared KF selected for 
encapsulation (2.104 µm ); B. polyelectrolyte encapsulated 
KF(2.208 µm ). 
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A. Photomicrograph of bared KF at magnification 
(100x) showed mono-dispersity. 
B. Photomicrograph of encapsulated KF at 
magnification 100x.
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Figure shows Log% cumulative KF released Vs log time plot of 
KF released at pH=4.5 
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IN-VITRO KF RELEASE  PROFILE
Cumulative % KF  release Vs Time 0.8 hr plot
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Figure shows in-vitro release profile of KF
 encapsulated formulations at pH=4.5.
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